STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORKA
  4. [Form 4] Oruka Therapeutics, Inc. Insider Trading Activity

Oruka Therapeutics (ORKA) grants stock and options to General Counsel

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. reported that its General Counsel, Paul T. Quinlan, received new equity awards on January 23, 2026.

He acquired 32,500 shares of common stock at a price of $0, held directly. This grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).

Quinlan was also granted an employee stock option for 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

Positive

  • None.

Negative

  • None.
Insider Quinlan Paul T
Role General Counsel
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 130,000 $0.00 --
Grant/Award Common Stock 32,500 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 130,000 shares (Direct); Common Stock — 32,500 shares (Direct)
Footnotes (1)
  1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Quinlan Paul T
(Last) (First) (Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100
(Street)
MENLO PARK CA 94025
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2026 A 32,500(1) A $0 32,500 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $34.39 01/23/2026 A 130,000 (2) 01/22/2036 Common Stock 130,000 $0 130,000 D
Explanation of Responses:
1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).
2. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
/s/ Paul Quinlan 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Oruka Therapeutics (ORKA) report for Paul Quinlan?

Oruka Therapeutics reported that General Counsel Paul T. Quinlan received a grant of 32,500 shares of common stock and an option to purchase 130,000 shares of common stock on January 23, 2026.

How many Oruka Therapeutics (ORKA) common shares did Paul Quinlan acquire?

Paul Quinlan acquired 32,500 shares of Oruka Therapeutics common stock at a price of $0 per share, all held as direct ownership after the transaction.

What are the key terms of Paul Quinlans stock option grant at Oruka Therapeutics (ORKA)?

Quinlan received an employee stock option covering 130,000 shares of Oruka Therapeutics common stock with an exercise price of $34.39 per share and an expiration date of January 22, 2036.

How does the common stock grant to Paul Quinlan at Oruka Therapeutics vest?

The 32,500-share common stock grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14, or the immediately preceding trading day if those dates are not trading days.

What is the vesting schedule for Paul Quinlans 130,000-share stock option at Oruka Therapeutics (ORKA)?

The 130,000-share stock option vests as to 1/48 of the underlying shares monthly starting from January 1, 2026, with the option expiring on January 22, 2036.

Is Paul Quinlans ownership in Oruka Therapeutics reported as direct or indirect?

Both the 32,500 common shares and the 130,000-share stock option are reported as direct (D) ownership, with no separate entity listed for indirect beneficial ownership.